Prosecution Insights
Last updated: April 18, 2026
Application No. 18/188,003

AMIDE COMPOUND

Final Rejection §103§112
Filed
Mar 22, 2023
Examiner
MCDONOUGH, JAMES E
Art Unit
1734
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Daikin Industries Ltd.
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
3y 2m
To Grant
82%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
1017 granted / 1425 resolved
+6.4% vs TC avg
Moderate +11% lift
Without
With
+11.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
50 currently pending
Career history
1475
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
59.6%
+19.6% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
10.3%
-29.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1425 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 uses an ASTM limitation which makes the claim indefinite. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim 1-9 and 13-16 are rejected under 35 U.S.C. 103 as being unpatentable over Oshima et al. (US 2021/0108371). Regarding claim 1, 3-7, 9 Oshima discloses a paper (i.e., a polymer made from cellulose, i.e., a sugar) comprising a layer formed on a surface thereof, wherein the layer comprises a graft chain formed from a compound (A), wherein the fourth structure shown reads directly on or makes the claimed amide compound obvious where the long chain hydrocarbon group (R3) is 13 to 27 carbon atoms (claim 13). With respect to the limitation on being biobased, it is noted that such is a product-by-process limitation, and does not add to the patentability of a composition claim unless it can be shown that the method used will result in a materially different product. With respect to the limitation of being configured to be applied to a substrate, it is noted before the graft chain is grafted to the paper (i.e., substrate) it is necessarily configured to be applied to a substrate, and is then indeed applied to a substrate. Regarding claim 2 The compound of Oshima meets the first formula. Regarding claim 8 The percentage of the compound that is biobased is a product-by-process limitation, and nothing in the record shows that the source from which the compounds are derived will result in a materially different composition. Regarding claims 13-15 Oshima discloses the use of a solvent such as water (para 0091-0092). Regarding claim 16 The source from which the carbon is derived is a product-by-process limitation, and applicants have not shown that the process used will result in a materially different product. Response to Arguments Applicants argue against the 112 rejection. Applicants argue that the use of ASTM in the claim does not make it indefinite. This is not persuasive as ASTM standards are not static and may change overtime. As such the use of an ASTM standard in the claims, make the claim indefinite as it cannot be determined what are the metes and bound of the claim. Applicants argue against the prior art rejections. Applicants argue that the compound (A) would not be an agent. This is not persuasive and before the compound is grafted to the paper it would be an agent. Applicants argue that compound (A) does not meet the requirements of claim 1. This is not persuasive and applicants have failed to point to any limitations which are not met. Applicants argue that compound (A) is not a compound. This is not persuasive as even applicants call it a compound. Further, before the compound is grafted to the paper it will be a separate and distinct compound. Applicants argue that their compound is configured to be applied to a substrate. While this may be true it is not persuasive as compound (A) is also configured to be applied to a substrate. Applicants argue that the use of water only applies to the solution of compound (A). This is not persuasive as all the claim requires is the amide compound and water. Applicants argue that the solution does not contain the biobased material. This is not persuasive as the solution is applied to paper, and when it is the limitations of the claim are met. The remaining arguments have been fully considered but are not persuasive for the same reasons given above. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES E MCDONOUGH whose telephone number is (571)272-6398. The examiner can normally be reached Mon-Fri 10-10. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jonathan Johnson can be reached at 5712721177. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JAMES E. MCDONOUGH Examiner Art Unit 1734 /JAMES E MCDONOUGH/Primary Examiner, Art Unit 1734
Read full office action

Prosecution Timeline

Mar 22, 2023
Application Filed
Aug 07, 2025
Non-Final Rejection — §103, §112
Nov 07, 2025
Response Filed
Dec 10, 2025
Final Rejection — §103, §112
Jan 27, 2026
Interview Requested
Feb 11, 2026
Examiner Interview Summary
Feb 11, 2026
Applicant Interview (Telephonic)
Apr 13, 2026
Request for Continued Examination
Apr 16, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12603189
DEVICES, SYSTEMS, AND METHODS FOR CLOSURE OF DEEP GEOLOGICAL NUCLEAR WASTE DISPOSAL REPOSITORY
2y 5m to grant Granted Apr 14, 2026
Patent 12600672
DECARBONIZED CEMENT BLENDS
2y 5m to grant Granted Apr 14, 2026
Patent 12590007
ZEOLITE NANOTUBES AND METHODS OF MAKING AND USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12576482
POROUS COATED ABRASIVE ARTICLE AND METHOD OF MAKING THE SAME
2y 5m to grant Granted Mar 17, 2026
Patent 12577160
AIR-DRY SCULPTURAL AND MODELING CLAY
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
82%
With Interview (+11.0%)
3y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 1425 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month